Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its small-molecule multi-kinase inhibitor, CSCJC3456. This molecule is now set to be evaluated in the context of general advanced malignant solid tumors.
CSCJC3456 is designed to selectively inhibit targets such as FGFR/KIT/RET/TRK, thereby exerting inhibitory effects on tumor cell proliferation, neovascularization, and tumor apoptosis. Pre-clinical studies have demonstrated that CSCJC3456 possesses potent anti-tumor effects against a variety of cancers, suggesting its potential to offer significant therapeutic benefits in future clinical applications.- Flcube.com
